INTRODUCTION
I nfantile hemangioma (IH) is the most common soft tissue tumor of childhood. Although most IH are uncomplicated and do not require intervention, they can be a significant source of parental distress, cosmetic disfigurement, and morbidity. [1] Hemangiomas affect nearly 4-10% of infants and have been found to have unique, but natural phases of proliferation (growth) and involution (dissolution). [2] Most hemangiomas regress with age and only approximately 10% will require intervention. [3] We present a child with diffuse pedunculated IH managed with propranolol and timolol.
CASE REPORT
A 4-month-old female child was admitted with multiple skin swellings noticed since 2 weeks of age. She was delivered as a full term baby by elective cesarean section after an uneventful pregnancy. 2 weeks after birth, the parents noticed small erythematous area on the face, which subsequently developed into a fine telangiectatic pattern and strawberry colored macules on the skin diffusely involving one-half of the face and head, trunk, hands, and the legs. negative for any bacterial growth. Biopsy of the skin lesion showed features suggestive of hemangioma. With this, a diagnosis of diffuse pedunculated IH was made.
The decision to intervene was made due to the extensive size of the hemangioma, diffuse pattern, and difficulty of feeding due to recurrent bleeding from the ulcerated areas on the upper lip. A potential complication that was considered and emphasized the need for intervention was the risk of delayed language development due to partial obstruction of the auditory canal on the right side which was noticed upon examination.
The infant was started on propranolol 1 mg/kg/day in divided doses, with gradual increasing of the dose as tolerated. Baseline electrocardiogram, echocardiogram, and laboratory evaluations were normal. Monitoring of heart rate, blood pressure, and blood glucose was performed. Dermatology reference was taken who advised timolol maleate drops on the lesions.
The patient was followed up in the ward on a daily basis and in the dermatology clinics. The hemangioma showed a significant improvement in size and color after 2 weeks from starting therapy and continued to shrink in size. Patient was discharged and advised to follow-up in Pediatric and Dermatology outpatient departments.
DISCUSSION
Hemangiomas are the most common benign tumor in infancy. The various problematic hemangiomas will develop rapidly and interfere with normal function and appearance. These problematic hemangiomas require intervention to control growth and reduce the likelihood of imminent functional and cosmetic deformities. [4] Propranolol was discovered serendipitously by Léauté-Labrèze et al., to induce accelerated involution of hemangioma. [5] Oral corticosteroids are still considered the first-line therapy for hemangiomas, but long-term and high-dosage steroid therapy has numerous side effects. The mechanism of action of propranolol can be attributed to vasoconstriction (early), blocking of proangiogenic signals (intermediate), and induction of apoptosis in proliferating endothelial cells (late). [6] A few recent studies have demonstrated an excellent efficacy of propranolol over corticosteroids without any failure. [7] Propranolol may limit the need for surgery in IH. [8] We used the dose of 1 mg/kg/day in EDD in our patient. Propranolol therapy requires careful monitoring of the infant for bradycardia, hypotension, hypoglycemia, and hypothermia. Other side effects of propranolol include bronchospasm especially in patients with reactive airway disease, skin rashes, fatigue, sleep disturbance, and gastrointestinal discomfort. [9] Therefore, we opted to admit the patient for the first 2 weeks of therapy for evaluation and monitoring purposes, and our patient tolerated the treatment very well without any adverse events.
Timolol is a nonselective topical β-adrenergic antagonist that has been used in ophthalmology for >30 years. The predominant adverse effects include hypotension, hypoglycemia, bronchospasm, and local pruritus. In our patient, the drug was topically applied to the skin lesions except face and therefore, there was likely to be minimal absorption the bloodstream. As expected, no systemic adverse reactions were observed during the treatment period of the study. Topical timolol treatment in superficial IH presents numerous advantages and appears particularly useful as an effective, safe, and relatively convenient treatment for this subtype of IH in patients up to 6 months of age. [10] Financial Support and Sponsorship Nil.
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